MCID: FLL022
MIFTS: 29

Fallopian Tube Clear Cell Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Clear Cell Adenocarcinoma

MalaCards integrated aliases for Fallopian Tube Clear Cell Adenocarcinoma:

Name: Fallopian Tube Clear Cell Adenocarcinoma 12 15 71
Clear Cell Carcinoma of the Fallopian Tube 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5301
NCIt 50 C6280
UMLS 71 C1333591

Summaries for Fallopian Tube Clear Cell Adenocarcinoma

Disease Ontology : 12 A fallopian tube adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Fallopian Tube Clear Cell Adenocarcinoma, also known as clear cell carcinoma of the fallopian tube, is related to adenocarcinoma and fallopian tube carcinoma. An important gene associated with Fallopian Tube Clear Cell Adenocarcinoma is BRCA2 (BRCA2 DNA Repair Associated), and among its related pathways/superpathways are Gastric cancer and Chks in Checkpoint Regulation. The drugs Topotecan and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary and endothelial, and related phenotypes are Decreased homologous recombination repair frequency and Decreased homologous recombination repair frequency

Related Diseases for Fallopian Tube Clear Cell Adenocarcinoma

Diseases related to Fallopian Tube Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.1 BRCA2 BRCA1
2 fallopian tube carcinoma 30.1 BRCA2 BRCA1
3 fallopian tube adenocarcinoma 10.2
4 clear cell adenocarcinoma 10.2
5 cancerophobia 9.9 BRCA2 BRCA1
6 ovary transitional cell carcinoma 9.9 BRCA2 BRCA1
7 basaloid lung carcinoma 9.9 BRCA2 BRCA1
8 nosophobia 9.9 BRCA2 BRCA1
9 familial ovarian cancer 9.9 BRCA2 BRCA1
10 hereditary site-specific ovarian cancer syndrome 9.9 BRCA2 BRCA1
11 tetraploidy 9.9 BRCA2 BRCA1
12 b-lymphoblastic leukemia/lymphoma 9.9 BRCA2 BRCA1
13 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 9.9 BRCA2 BRCA1
14 breast-ovarian cancer, familial 2 9.9 BRCA2 BRCA1
15 intracystic papillary adenoma 9.9 BRCA2 BRCA1
16 endosalpingiosis 9.9 BRCA2 BRCA1
17 cervical adenoma malignum 9.9 BRCA2 BRCA1
18 synchronous bilateral breast carcinoma 9.9 BRCA2 BRCA1
19 mutagen sensitivity 9.9 BRCA2 BRCA1
20 primary peritoneal carcinoma 9.9 BRCA2 BRCA1
21 dysplastic nevus syndrome 9.9 BRCA2 BRCA1
22 hypertrophy of breast 9.9 BRCA2 BRCA1
23 female reproductive endometrioid cancer 9.9 BRCA2 BRCA1
24 peritoneum cancer 9.9 BRCA2 BRCA1
25 breast-ovarian cancer, familial 1 9.9 BRCA2 BRCA1
26 papillary serous adenocarcinoma 9.9 BRCA2 BRCA1
27 fallopian tube disease 9.9 BRCA2 BRCA1
28 hereditary nonpolyposis colon cancer 9.9 BRCA2 BRCA1
29 lobular neoplasia 9.9 BRCA2 BRCA1
30 thoracic benign neoplasm 9.9 BRCA2 BRCA1
31 breast benign neoplasm 9.9 BRCA2 BRCA1
32 fanconi anemia, complementation group d1 9.9 BRCA2 BRCA1
33 myasthenic syndrome, congenital, 6, presynaptic 9.9 BRCA2 BRCA1
34 ovarian cystadenocarcinoma 9.9 BRCA2 BRCA1
35 dysgerminoma 9.9 BRCA2 BRCA1
36 uterine corpus cancer 9.9 BRCA2 BRCA1
37 fanconi anemia, complementation group j 9.9 BRCA2 BRCA1
38 papillary adenocarcinoma 9.9 BRCA2 BRCA1
39 bilateral breast cancer 9.8 BRCA2 BRCA1
40 female breast cancer 9.8 BRCA2 BRCA1
41 ovary adenocarcinoma 9.8 BRCA2 BRCA1
42 pre-malignant neoplasm 9.8 BRCA2 BRCA1
43 gastric cancer, hereditary diffuse 9.8 BRCA2 BRCA1
44 serous cystadenocarcinoma 9.8 BRCA2 BRCA1
45 sporadic breast cancer 9.8 BRCA2 BRCA1
46 in situ carcinoma 9.8 BRCA2 BRCA1
47 breast carcinoma in situ 9.8 BRCA2 BRCA1
48 bloom syndrome 9.8 BRCA2 BRCA1
49 ductal carcinoma in situ 9.8 BRCA2 BRCA1
50 malignant ovarian surface epithelial-stromal neoplasm 9.8 BRCA2 BRCA1

Graphical network of the top 20 diseases related to Fallopian Tube Clear Cell Adenocarcinoma:



Diseases related to Fallopian Tube Clear Cell Adenocarcinoma

Symptoms & Phenotypes for Fallopian Tube Clear Cell Adenocarcinoma

GenomeRNAi Phenotypes related to Fallopian Tube Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 9.92 BRCA1
2 Decreased homologous recombination repair frequency GR00151-A-2 9.92 BRCA1
3 Decreased homologous recombination repair frequency GR00236-A-1 9.92 BRCA1 BRCA2
4 Decreased homologous recombination repair frequency GR00236-A-2 9.92 BRCA1 BRCA2
5 Decreased homologous recombination repair frequency GR00236-A-3 9.92 BRCA1 BRCA2
6 Decreased viability after ionizing radiation GR00232-A-2 9.26 BRCA1 BRCA2
7 Decreased viability with cisplatin GR00101-A-4 9.16 BRCA1 BRCA2
8 Synthetic lethal with cisplatin GR00101-A-1 8.96 BRCA1 BRCA2
9 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 8.62 BRCA1 BRCA2

Drugs & Therapeutics for Fallopian Tube Clear Cell Adenocarcinoma

Drugs for Fallopian Tube Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
2
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
3
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
4
Bevacizumab Approved, Investigational Phase 3 216974-75-3
5
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
6
Olaparib Approved Phase 3 763113-22-0 23725625
7
Gemcitabine Approved Phase 3 95058-81-4 60750
8
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
9
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
10 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
11
Cediranib Investigational Phase 3 288383-20-0 9933475
12
Maleic acid Experimental Phase 3 110-16-7 444266
13 Trace Elements Phase 3
14 Carotenoids Phase 3
15 Micronutrients Phase 3
16 topoisomerase I inhibitors Phase 2, Phase 3
17 Antimitotic Agents Phase 3
18 Albumin-Bound Paclitaxel Phase 3
19 Tubulin Modulators Phase 3
20 taxane Phase 3
21 Immunoglobulin G Phase 3
22 Antineoplastic Agents, Immunological Phase 3
23 Angiogenesis Inhibitors Phase 3
24 Immunoglobulins Phase 3
25 Immunologic Factors Phase 3
26 Mitogens Phase 3
27 Immunoglobulins, Intravenous Phase 3
28 Antibodies, Monoclonal Phase 3
29 Antibodies Phase 3
30 Endothelial Growth Factors Phase 3
31 Antibiotics, Antitubercular Phase 3
32 Anti-Bacterial Agents Phase 3
33 Protein Kinase Inhibitors Phase 3
34
Liposomal doxorubicin Phase 3 31703
35 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
36 Immunosuppressive Agents Phase 3
37 Anti-Infective Agents Phase 3
38 Antiviral Agents Phase 3
39 Antimetabolites Phase 3
40
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
41
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
42
Pembrolizumab Approved Phase 2 1374853-91-4
43
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
44 Pharmaceutical Solutions Phase 2
45 Antirheumatic Agents Phase 2
46 Alkylating Agents Phase 2
47
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
48
Propranolol Approved, Investigational Early Phase 1 525-66-6 4946
49
Levoleucovorin Approved, Investigational Early Phase 1 68538-85-2 149436
50
Folic acid Approved, Nutraceutical, Vet_approved Early Phase 1 59-30-3 6037

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
2 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
3 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
4 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
5 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
6 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
7 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
8 A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum Completed NCT02315430 Phase 2 Cabozantinib S-malate
9 Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
10 A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
11 A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02853318 Phase 2 Cyclophosphamide
12 A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
13 A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) Recruiting NCT04092270 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride;Peposertib
14 Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Completed NCT01504126 Early Phase 1 Chemotherapy;Propranolol Hydrochloride
15 A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer Active, not recruiting NCT02111941 Early Phase 1

Search NIH Clinical Center for Fallopian Tube Clear Cell Adenocarcinoma

Genetic Tests for Fallopian Tube Clear Cell Adenocarcinoma

Anatomical Context for Fallopian Tube Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Fallopian Tube Clear Cell Adenocarcinoma:

40
Ovary, Endothelial

Publications for Fallopian Tube Clear Cell Adenocarcinoma

Articles related to Fallopian Tube Clear Cell Adenocarcinoma:

# Title Authors PMID Year
1
Primary Fallopian Tube Clear Cell Adenocarcinoma in Pregnancy: Case Presentation and Review of the Literature. 61
26090245 2015

Variations for Fallopian Tube Clear Cell Adenocarcinoma

Expression for Fallopian Tube Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Fallopian Tube Clear Cell Adenocarcinoma.

Pathways for Fallopian Tube Clear Cell Adenocarcinoma

Pathways related to Fallopian Tube Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.14 BRCA2 BRCA1
2
Show member pathways
12.06 BRCA2 BRCA1
3
Show member pathways
12.03 BRCA2 BRCA1
4 11.88 BRCA2 BRCA1
5
Show member pathways
11.83 BRCA2 BRCA1
6
Show member pathways
11.62 BRCA2 BRCA1
7 11.44 BRCA2 BRCA1
8
Show member pathways
11.33 BRCA2 BRCA1
9 10.92 BRCA2 BRCA1
10
Show member pathways
10.54 BRCA2 BRCA1

GO Terms for Fallopian Tube Clear Cell Adenocarcinoma

Cellular components related to Fallopian Tube Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA2 BRCA1

Biological processes related to Fallopian Tube Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA repair GO:0006281 9.4 BRCA2 BRCA1
2 DNA recombination GO:0006310 9.37 BRCA2 BRCA1
3 double-strand break repair via homologous recombination GO:0000724 9.32 BRCA2 BRCA1
4 double-strand break repair GO:0006302 9.26 BRCA2 BRCA1
5 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.16 BRCA2 BRCA1
6 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.96 BRCA2 BRCA1
7 chordate embryonic development GO:0043009 8.62 BRCA2 BRCA1

Sources for Fallopian Tube Clear Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....